OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Herzog on the FDA Approval of Mirvetuximab Soravtansine in FRα–positive Gynecologic Cancers

February 6th 2023

Thomas Herzog, MD, discusses how the recent FDA approval of the novel antibody-drug conjugate mirvetuximab soravtansine-gynx ameliorates unmet need in platinum-resistant, folate receptor alpha–positive gynecological cancers.

Dr. Park on Determining Treatment Approaches in NSCLC

February 6th 2023

Henry S. Park, MD, MPH, discusses key considerations when selecting an optimal treatment approach for patients with stage II and III non–small cell lung cancer.

Dr. Grivas on Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma

February 6th 2023

Petros Grivas, MD, PhD, discusses the investigation of enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma.

Dr. Crown on the Investigation of Lapatinib Plus Chemotherapy in HER2+ Breast Cancer

February 3rd 2023

John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.

Dr. Kuykendall on the Evaluation of Momelotinib in Myelofibrosis

February 3rd 2023

Andrew Kuykendall, MD, discusses the evaluation of momelotinib in patients with symptomatic and anemic myelofibrosis.

Dr. Boughey on Key Results From the ACOSOG Z11102 Trial in Multiple Ipsilateral Breast Cancer

February 3rd 2023

Judy C. Boughey, MD, discusses the significance of results from the phase 2 ACOSOG Z11102 trial evaluating breast conserving therapy in multiple ipsilateral breast cancer.

Dr. Khoury on the Importance of Differentiating Between BPDCN and AML

February 2nd 2023

Joseph D. Khoury, MD, discusses the importance of differentiating between blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia.

Dr. Daver on Unmet Needs in the Treatment of BPDCN

February 2nd 2023

Naval Daver, MD, discusses the unmet needs for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.

Dr. Lang on the Potential Applications for the Parsortix® PC1 System in Breast Cancer

February 2nd 2023

Julie Lang, MD, discusses potential applications for the Parsortix® PC1 system in metastatic breast cancer.

Dr. Wang on Expanding the Role of MRD Testing in AML

February 2nd 2023

Eunice Wang, MD, discusses the utility of minimal residual disease testing in hematologic malignancies and challenges associated with expanding its role in clinical practice for acute myeloid leukemia.

Dr. Borad on the Use of Next-Generation FGFR Inhibitors in Cholangiocarcinoma and Urothelial Carcinoma

February 2nd 2023

Mitesh J. Borad, MD, discusses the unique mechanism of action of next-generation FGFR inhibitors like KIN-3248 and their potential effect on patient outcomes in cholangiocarcinoma and urothelial cancer.

Dr. Siegel on Updated Results From the KarMMA-2 Trial in R/R Multiple Myeloma

February 2nd 2023

David Siegel, MD, discusses the significance of updated data from cohort 2C of the phase 2 KarMMa-2 trial in multiple myeloma.

Dr. Searle on Initial Results From the MajesTEC-2 Trial in Multiple Myeloma

February 2nd 2023

Emma Searle, MD, discusses early findings from cohort E of the phase 1b MajesTEC-2 trial (NCT04722146) evaluating teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) and lenalidomide (Revlimid) in multiple myeloma.

Dr. Herbst on the FDA Approval of Adjuvant Pembrolizumab in NSCLC

February 2nd 2023

Roy S. Herbst, MD, PhD, discusses the significance of the FDA approval of adjuvant pembrolizumab in patients with non–small cell lung cancer.

Dr. Moghanaki on Remaining Questions Following the CheckMate-816 Trial in NSCLC

February 1st 2023

Drew Moghanaki, MD, MPH, discusses questions that still need to be addressed following the phase 3 CheckMate-816 trial of the neoadjuvant combination nivolumab plus chemotherapy in patients with non–small cell lung cancer.

Dr. Ramnaraign on the Evaluation of Atezolizumab Plus Tivozanib in GI Malignancies

February 1st 2023

Brian Ramnaraign, MD, discusses the evaluation of atezolizumab plus tivozanib in a phase 1b/2 trial in patients with pancreatic, gallbladder, and bile duct cancers.

Dr. Costa on the Efficacy of Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage TNBC

February 1st 2023

Ricardo Costa, MD, MSC, discusses the use of neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab monotherapy, in patients with high-risk, early-stage triple-negative breast cancer.

Dr. Maris on Key Results From the OUTREACH Trial of Liso-cel in DLBCL

February 1st 2023

Michael Maris, MD, discusses key efficacy and safety data from the phase 2 OUTREACH trial in diffuse large B-cell lymphoma.

Dr. Gandhi on Key Interim Results From the SGN35-027 Trial in Hodgkin Lymphoma

February 1st 2023

Mitul Gandhi, MD, discusses key findings from part C of the phase 2 SGN35-027 trial in Hodgkin lymphoma.

Dr. Fakih on Tumor Microenvironment Differences in MSS mCRC

February 1st 2023

Marwan G. Fakih, MD, discusses a comparative analysis of the tumor microenvironment in primary tumors vs metastatic tissue in patients with microsatellite stable metastatic colorectal cancer.